Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGFBP3 | P17936 | 11/20 | 0.43 |
| ▸ | IGFBP5 | P24593 | 4/20 | 0.43 |
| ▸ | IGFBP1 | P08833 | 1/20 | 0.43 |
| ▸ | IGFBP2 | P18065 | 1/20 | 0.43 |
| ▸ | IGFBP4 | P22692 | 1/20 | 0.43 |
| ▸ | IGFBP6 | P24592 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2903071 | 0.89 | IGFBP3 (0.44) | IGFBP3IGFBP5IGFBP1IGFBP2IGFBP4 | |
| SCHEMBL2902980 | 0.89 | ALOX15 (0.47) | IGFBP3IGFBP5IGFBP1IGFBP2IGFBP4 | |
| SCHEMBL2909268 | 0.84 | LCK (0.44) | MAPTALDH1A1HPGDALOX15TSHR | |
| SCHEMBL2905327 | 0.81 | GRM2 (0.49) | IGFBP3IGFBP5MAPTALDH1A1ALOX15 | |
| SCHEMBL6593084 | 0.81 | KDM4E (0.53) | MAPTALDH1A1PKMKDM4ERAB9A | |
| SCHEMBL2905794 | 0.80 | IGFBP5 (0.46) | IGFBP3IGFBP5MAPTALDH1A1ALOX15 | |
| SCHEMBL2908172 | 0.78 | CSNK2A1 (0.46) | ALDH1A1TDP1TSHRKDM4ERAB9A | |
| SCHEMBL2909734 | 0.78 | MCL1 (0.44) | IGFBP3IGFBP5ALDH1A1ALOX15KDM4E | |
| 7-Chlorokynurenic Acid SCHEMBL31238955 | 0.78 | IGFBP3 (0.47) | IGFBP3IGFBP5ALDH1A1HPGDHIF1A | |
| SCHEMBL2909106 | 0.78 | IGFBP5 (0.45) | IGFBP3IGFBP5ALDH1A1ALOX15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578423-B1 | 2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | BAYER SCHERING PHARMA AG (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-7176207-B2 | Anticoagulants; antithrombotic agents in the treatment and prevention of thrombosis | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-02-13 | — | — | US | disclosed |
| US-7084142-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-08-01 | — | — | US | disclosed |
| US-20060135532-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-22 | — | — | US | disclosed |
| US-20060122188-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-08 | — | — | US | disclosed |
| US-7056923-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-06 | — | — | US | disclosed |
| US-7026323-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-04-11 | — | — | US | disclosed |
| US-6995156-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-02-07 | — | — | US | disclosed |
| EP-1578423-A1 | 2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-09-28 | — | — | EP | disclosed |
| US-20050065163-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-24 | — | — | US | disclosed |
| US-6861424-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-01 | — | — | US | disclosed |
| US-20050038037-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-02-17 | — | — | US | disclosed |
| US-20040138229-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | US | disclosed |
| WO-2004052366-A1 | 2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | WO | disclosed |
| US-20030060474-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122188-A1 | Platelet adenosine diphosphate receptor antagonists | TBXA2R, P2RY1, ADORA1 | IGFBP3 4170/4885IGFBP5 4143/4885IGFBP1 3813/4885 |
| US-20050065163-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA2B, ADORA1, TBXA2R | IGFBP3 3464/4885IGFBP5 3445/4885IGFBP1 2586/4885 |
| US-20050038037-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA2B, ADORA1, TBXA2R | IGFBP3 3464/4885IGFBP5 3445/4885IGFBP1 2586/4885 |
| US-20040138229-A1 | Platelet adenosine diphosphate receptor antagonists | TBXA2R, ADORA1, P2RY1 | IGFBP3 3914/4885IGFBP5 4245/4885IGFBP1 3225/4885 |
| US-20030060474-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA1, TBXA2R, ADORA2B | IGFBP3 3531/4885IGFBP5 3553/4885IGFBP1 2199/4885 |
| US-20060135532-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA1, ADORA2B, TBXA2R | IGFBP3 3490/4885IGFBP5 3455/4885IGFBP1 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.